1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
698E367068F131159002586F500393A6C
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-2025-moving-next-level-by-redefining-virtual-capabilities-evidence-generation-value-communication?opendocument
18
19opendocument
203.239.58.199
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Affairs Excellence

Medical Affairs 2025: Moving to the Next Level by Redefining Virtual Capabilities, Evidence Generation and Value Communication

ID: 5683


Features:

6 Info Graphics

13 Data Graphics

120+ Metrics

8 Narratives


Pages/Slides: 28


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Medical Affairs 2025: Moving to the Next Level by Redefining Virtual Capabilities, Evidence Generation and Value Communication”

STUDY OVERVIEW

The last decade has seen Medical Affairs move from a support function to what many view as the third leadership pillar in biopharma. While the pace of change has considerably altered the healthcare landscape in the last few years, the global COVID-19 pandemic has triggered a tsunami of rapid structural and technology changes for Medical Affairs in particular.

A rapidly changing world for Medical Affairs will also see new opportunities and growth levels as we approach 2025.

Best Practices, LLC undertook this research to explore a four-year future horizon for Medical Affairs. This research examines evolving tools, technologies, value fronts, and structures. It further explores the direction and velocity of change.

KEY TOPICS

  • Medical Affairs Priorities for 2025
  • Medical Affairs Hybrid Workplace and Digital Transformation
  • Evidence Generation in 2025
  • Key Medical Affairs Responsibilities by 2025
  • Medical Affairs Value Communication
  • Optimizing Structure of Medical Affairs in 2025

KEY METRICS
  • Is the concept of an office-based Medical Affairs employee a thing of the past in the post COVID era?
  • What type of virtual capabilities are you using / exploring since the start of the COVID-19 pandemic?
  • What groups will have greater and lesser importance by 2025?
  • What roles does your Medical Affairs Organization take to showcase value?
  • What are key responsibilities for Medical Affairs now? In 2025?
  • What will the structure of Medical Affairs (from a sub-function standpoint) look like in 2025?

SAMPLE KEY FINDINGS
  • Digital Transformation: Post COVID, the majority of companies will use hybrid medical approaches for various group and functional roles. Digital technologies will extend reach, function and productivity across multiple groups within medical.
  • Evolution of RWE: Real world evidence is accelerating through technological advancements, greater payer focus, expanding MSL roles, and upgrading patient management pathways.

METHODOLOGY

Best Practices, LLC developed a benchmark protocol that examines current and future medical operations, capabilities, and performance. The research analysis engaged 74 executives from 57 leading life sciences companies. Chief Medical Officers and Medical Directors represent nearly 80% of the leaders who reflected on current medical trends and future directions in this study.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Medical Device; Diagnostic; Health Care; Medical; Consulting; Consumer Products; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Adamas Pharmaceuticals; Alkermes; Apellis Pharmaceuticals; ASC Therapeutics; Astellas; AstraZeneca; Aziyo Biologics; Inc.; Baxter Healthcare; BioMarin; bioMerieux; Boehringer Ingelheim; Castle Creek Biosciences; Cipla; Clovis Oncology; Eisai; Eli Lilly; EMD Serono; Gama PharMed Solutions Limited; Glenmark; Gossamer Bio; Greenwich Biosciences; Ipsen; Jazz Pharmaceuticals; Johnson & Johnson; Leica Biosystems; LEO Pharma; Lundbeck; Maxwell Clinic; MEDiSTRAVA; Melinta Therapeutics; Inc; Merck; Milestone Pharmaceuticals; Natera; NexGen Pharma; Novartis; Novavax; Novo Nordisk; Orion Pharmaceuticals; Pfizer; Partner Therapeutics (PTx); Regeneron; Roche; Sandoz; Sanofi; Sanofi Genzyme; Santen; Servier; Sunovion; Takeda Pharmaceuticals; Terumo Corporation; Teva Pharmaceutical Industries Ltd; United Therapeutics; Virbac; Zoetis Inc.

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.